Drug Profile
Panitumumab biosimilar - PanPharmaceuticals USA
Latest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator PanPharmaceuticals USA
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 17 Jun 2015 Discontinued for Colorectal cancer in USA (unspecified route)
- 17 Jun 2015 PanPharmaceuticals USA has ceased its operations